Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · Real-Time Price · USD
1.210
0.00 (0.00%)
At close: Apr 28, 2026, 4:00 PM EDT
1.200
-0.010 (-0.83%)
After-hours: Apr 28, 2026, 4:09 PM EDT
Pliant Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Pliant Therapeutics stock have an average target of 2.67, with a low estimate of 2.00 and a high estimate of 3.00. The average target predicts an increase of 120.66% from the current stock price of 1.21.
Analyst Consensus: Hold
* Price targets were last updated on Mar 13, 2026.
Analyst Ratings
The average analyst rating for Pliant Therapeutics stock from 4 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 9 | 9 | 9 | 9 | 3 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $4 → $3 | Hold | Maintains | $4 → $3 | +147.93% | Mar 13, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $4 → $3 | Buy | Maintains | $4 → $3 | +147.93% | Mar 12, 2026 |
| RBC Capital | RBC Capital | Hold Maintains $3 → $2 | Hold | Maintains | $3 → $2 | +65.29% | Nov 7, 2025 |
| JP Morgan | JP Morgan | Hold → Sell Downgrades n/a | Hold → Sell | Downgrades | n/a | n/a | Oct 10, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $17 → $4 | Buy | Maintains | $17 → $4 | +230.58% | Aug 8, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.54
from -2.43
EPS Next Year
-1.22
from -1.54
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.30 | 0.48 | ||||||
| Avg | -1.54 | -1.22 | ||||||
| Low | -1.74 | -2.13 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.